Clinical Trial Update: Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of Bevacizumab, Erlotinib, and Atezolizumab for advanced renal cell carcinoma. The study is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Leiomyomatosis and Renal Cell Carcinoma
• Papillary Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma | Phase 2 | Status: RECRUITING